Paper Details

  1. Home
  2. Paper Details

Assessing methylphenidate preference in ADHD patients using a choice procedure.

Author: FredericksEmily MacDonald, KollinsScott H

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Methylphenidate (MPH) is a common treatment for attention deficit hyperactivity disorder (ADHD). This study found that adults with ADHD preferred MPH over a placebo, but this preference was likely due to the drug’s therapeutic effects rather than its potential for abuse. MPH choosers, those who reliably chose MPH over placebo, had higher levels of ADHD symptoms than those who did not choose MPH.
Paper Details　
Original Abstract of the Article :
RATIONALE: Methylphenidate (MPH) is widely used in the treatment of attention deficit hyperactivity disorder (ADHD) and is associated with positive clinical effects across a wide range of domains. Despite the clinical effectiveness of MPH, concern has arisen with respect to its abuse potential. OBJ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s00213-004-1838-2

データ提供：米国国立医学図書館（NLM）

Methylphenidate Preference in ADHD Patients: Exploring Therapeutic Efficacy and Abuse Potential

This research dives into the complex world of [attention deficit hyperactivity disorder (ADHD)] and its treatment with [methylphenidate (MPH)]. The researchers, like detectives investigating a perplexing case, sought to understand the factors influencing [MPH preference] in individuals with ADHD. Their findings offer valuable insights into the relationship between [drug preference], [therapeutic efficacy], and [abuse potential] in this patient population.

Exploring Methylphenidate Preference in Individuals with ADHD

The research, like a carefully conducted experiment in a desert lab, revealed that [MPH] was chosen significantly more often than [placebo] among individuals with ADHD. This suggests that [MPH] may be perceived as beneficial by many individuals with ADHD, potentially reflecting its therapeutic effects. However, the study also found that [MPH choosers] reported higher levels of [baseline ADHD symptoms], indicating a potential link between symptom severity and preference for MPH.

The Importance of Understanding Methylphenidate Preference in ADHD Treatment

These findings highlight the importance of understanding the factors influencing [MPH preference] in individuals with ADHD. The researchers caution against solely attributing preference to [abuse potential], suggesting that [therapeutic efficacy] may play a significant role. This research, like a map guiding us through the complexities of ADHD treatment, emphasizes the need for careful consideration of individual patient needs and responses to medication.

Dr. Camel's Conclusion

This study underscores the importance of carefully evaluating the factors influencing [MPH preference] in individuals with ADHD. The researchers' findings suggest that [MPH preference] may be driven by its therapeutic benefits rather than its abuse potential. Just as a camel navigates the desert using its senses and intuition, healthcare professionals must carefully consider the unique needs of each patient when determining the most appropriate treatment for ADHD.

Date :
  1. Date Completed 2005-01-26
  2. Date Revised 2019-12-10
Further Info :

Pubmed ID

15258716

DOI: Digital Object Identifier

10.1007/s00213-004-1838-2

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.